IDH1 mutation of gliomas with long-term survival analysis

Oncology Reports

Volumn 28, Issue 5, 2012, Pages 1639-1644

  Myung, Jae Kyung ^a   Cho, Hwa Jin ^a   Park, Chul Kee ^b   Kim, Seung Ki ^c   Phi, J I Hoon ^c   Park, Sung Hye ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Brain tumor; Glioma; Isocitrate dehydrogenase; Mutation

Indexed keywords

ARGININE; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTIDINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CONTROLLED STUDY; EGFR GENE; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE 1 GENE; LONG TERM SURVIVAL; MALE; MUTATIONAL ANALYSIS; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; TUMOR GENE;

BASE SEQUENCE; BRAIN NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GENE AMPLIFICATION; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; OLIGODENDROGLIOMA; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84866443042     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1994     Document Type: Article

References (37)

1. Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812, 2008.
2. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C and von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116: 597-602, 2008.
3. Bleeker FE, Atai NA, Lamba S, et al: The prognostic IDH1 (R132) mutation is associated with reduced NADP (+)-dependent IDH activity in glioblastoma. Acta Neuropathol 119: 487-494 2010.
4. Bujko M, Kober P, Matyja E, et al: Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients. Mol Diagn Ther 14: 163-169, 2010.
5. Capper D, Weissert S, Balss J, et al: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20: 245-254, 2010.
6. Dang L, White DW, Gross S, et al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744, 2009.
7. De Carli E, Wang X and Puget S: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 2248; author reply 2249, 2009.
8. Dubbink HJ, Taal W, van Marion R, et al: IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73: 1792-1795, 2009.
9. Ducray F, Marie Y and Sanson M: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 2248; author reply 2249, 2009.
10. Ferroli P, Acerbi F and Finocchiaro G: From standard treatment to personalized medicine: role of IDH1 mutations in low-grade glioma evolution and treatment. World Neurosurg 73: 234-236, 2010.
11. Frezza C, Tennant DA and Gottlieb E: IDH1 mutations in gliomas: when an enzyme loses its grip. Cancer Cell 17: 7-9, 2010.
12. Gravendeel LA, Kloosterhof NK, Bralten LB, et al: Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat 31: E1186-E1199, 2010.
13. Hartmann C, Meyer J, Balss J, et al: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118: 469-474, 2009.
14. Hayden JT, Fruhwald MC, Hasselblatt M, Ellison DW, Bailey S and Clifford SC: Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children. Cell Cycle 8: 1806-1807, 2009.
15. Horbinski C, Kelly L, Nikiforov YE, Durso MB and Nikiforova MN: Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. TJ Mol Diagn 12: 487-492, 2010.
16. Horbinski C, Kofler J, Kelly LM, Murdoch GH and Nikiforova MN: Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 68: 1319-1325, 2009.
17. Houillier C, Wang X, Kaloshi G, et al: IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75: 1560-1566, 2010.
18. Ichimura K, Pearson DM, Kocialkowski S, et al: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neurooncology 11: 341-347, 2009.
19. Kang MR, Kim MS, Oh JE, et al: Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125: 353-355, 2009.
20. Komotar RJ, Starke RM, Sisti MB and Connolly ES: IDH1 and IDH2 mutations in gliomas and the associated induction of hypoxia-inducible factor and production of 2-hydroxyglutarate. Neurosurgery 66: N20-N21, 2010.
21. Larsen CJ: Mutations of IDH1 and 2 genes: a molecular diagnosis of low-grade gliomas. Bull Cancer 96: 641-642, 2009 (In French).
22. Nobusawa S, Watanabe T, Kleihues P and Ohgaki H: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15: 6002-6007, 2009.
23. Sanson M, Marie Y, Paris S, et al: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27: 4150-4154, 2009.
24. Sonoda Y, Kumabe T, Nakamura T, et al: Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100: 1996-1998, 2009.
25. Uno M, Oba-Shinjo SM, Silva R, et al: IDH1 mutations in a Brazilian series of glioblastoma. Clinics (Sao Paulo) 66: 163-165, 2011.
26. Van den Bent MJ, Dubbink HJ, Marie Y, et al: IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16: 1597-1604, 2010.
27. Watanabe T, Nobusawa S, Kleihues P and Ohgaki H: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174: 1149-1153, 2009.
28. Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773, 2009.
29. Zhao S, Lin Y, Xu W, et al: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324: 261-265, 2009.
30. Thol F, Weissinger EM, Krauter J, et al: IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 95: 1668-1674, 2010.
31. Murugan AK, Bojdani E and Xing M: Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun 393: 555-559, 2010.
32. Oki K, Takita J, Hiwatari M, et al: IDH1 and IDH2 mutations are rare in pediatric myeloid malignancies. Leukemia 25: 382-384, 2011.
33. Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W and Haferlach T: IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 116: 5486-5496, 2010.
34. Weller M, Felsberg J, Hartmann C, et al: Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27: 5743-5750, 2009.
35. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK and Kim WH: EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 52: 738-746, 2008. (Pubitemid 351600058)
36. Jeon YK, Park K, Park CK, Paek SH, Jung HW and Park SH: Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization. Neuropathology 27: 10-20, 2007. (Pubitemid 46146609)
37. Park CK, Park SH, Lee SH, et al: Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. Neuropathology 29: 443-449, 2009.